Gynecologic Cancers Archives - Page 3 of 39 - MPR

Gynecologic Cancers

MPR Weekly Dose Podcast: Episode 10

This week we talk about the resurrection of Biogen’s novel Alzheimer treatment; A “landmark” approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson & Johnson baby powder recall.

Combination Treatment Approved for Advanced Endometrial Carcinoma

The Food and Drug Administration (FDA) has approved the combination of pembrolizumab (Keytruda; Merck), a human programmed death receptor-1 (PD-1)-blocking antibody, and lenvatinib (Lenvima; Eisai), a kinase inhibitor, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic…

Biosimilars Mvasi, Kanjinti Now Available in the US

Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.  Mvasi, a vascular endothelial growth factor inhibitor, is indicated to treat: Metastatic colorectal cancer, in combination with intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment.  Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan-…